Celldex Therapeutics Inc. (CLDX) News
Filter CLDX News Items
CLDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLDX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CLDX News From Around the Web
Below are the latest news stories about CELLDEX THERAPEUTICS INC that investors may wish to consider to help them evaluate CLDX as an investment opportunity.
January 2025's Undervalued Small Caps With Insider Action On US MarketsOver the last 7 days, the United States market has experienced a 2.6% drop, yet it has shown resilience with a 24% rise over the past year and earnings projected to grow by 15% annually. In this dynamic environment, identifying small-cap stocks that are potentially undervalued and exhibit insider action can offer unique opportunities for investors seeking to capitalize on emerging growth prospects. |
Is There An Opportunity With Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) 26% Undervaluation?Key Insights Celldex Therapeutics' estimated fair value is US$33.97 based on 2 Stage Free Cash Flow to Equity Celldex... |
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic DermatitisHAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD is one of the most common chronic inflammatory skin diseases, with a lifetime prevalence of up to 20% of the US population and a substantial impact on quality of life1. Mast cells are strongly implicated in all facets of AD pathophysiology and the fu |
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory DiseasesHAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. “The introduction of our first bispecific candidat |
Celldex Therapeutics to Present at Upcoming Investor ConferencesHAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation Conference on Tuesday, November 12th at 4:00 p.m. ET 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 4:15 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex websi |
Celldex Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsCelldex Therapeutics ( NASDAQ:CLDX ) Third Quarter 2024 Results Key Financial Results Net loss: US$42.1m (loss widened... |
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue EstimatesCelldex (CLDX) delivered earnings and revenue surprises of 7.25% and 121.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Celldex: Q3 Earnings SnapshotHAMPTON, N.J. (AP) — Celldex Therapeutics Inc. CLDX) on Wednesday reported a loss of $42.1 million in its third quarter. On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 64 cents. |
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateEnrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of response and a favorable safety profile Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start in Q4 Celldex’s first bispecific for inflammatory diseases, CDX-622, to enter t |